Unknown PHASE2 INTERVENTIONAL 1-arm NCT04659434

Sintilimab Plus R-GemOx as Second-line Salvage Therapy in Patients With R/R DLBCL

A Phase II Study of Anti-PD-1 Antibody (Sintilimab) Plus Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Second-line Salvage Therapy in Patients With Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Sponsor: Qian Wenbin

Conditions Diffuse Large B Cell Lymphoma Refractory Diffuse Large B-Cell Lymphoma Relapsed Diffuse Large B-Cell Lymphoma

Interventions Sintilimab

Updated 4 times since 2021 Last updated: Dec 2, 2020 Started: Dec 10, 2020 Primary completion: Dec 10, 2022 Completion: Dec 10, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04659434, this PHASE2 trial focuses on Diffuse Large B Cell Lymphoma and Refractory Diffuse Large B-Cell Lymphoma and remains ongoing. Sponsored by Qian Wenbin, it has been updated 4 times since 2020, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

4 versions recorded

Jan 2026 — Present [monthly]

Unknown PHASE2

Status: Not Yet Recruiting → Unknown
Sep 2024 — Jan 2026 [monthly]

Not Yet Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE2
Jan 2021 — Jul 2024 [monthly]

Not Yet Recruiting PHASE2

First recorded

Dec 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Qian Wenbin

Data source: Second Affiliated Hospital, School of Medicine, Zhejiang University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hangzhou, China